SCHEMBL16209714

SCHEMBL16209714

NC(=O)c1ccc(C(=O)Nc2cc(F)ccc2O)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNMA1 Q12791 2/20 0.51
▸ P4HTM Q9NXG6 5/20 0.50
▸ HDAC1 Q13547 2/20 0.49
▸ MEN1 O00255 1/20 0.45
▸ AHR P35869 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ CCNT1 O60563 1/20 0.45
▸ CDK1 P06493 1/20 0.45
▸ CDK4 P11802 1/20 0.45
▸ CCNB1 P14635 1/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CCNE1 P24864 1/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ CCND3 P30281 1/20 0.45
▸ CDK9 P50750 1/20 0.45
▸ CDK3 Q00526 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16209413 0.91 KCNMA1 (0.52) KCNMA1P4HTMHDAC1MEN1AHR
SCHEMBL16209910 0.90 CXCR2 (0.51) P4HTMHDAC1MEN1AHRKMT2A
SCHEMBL16209815 0.85 KCNMA1 (0.60) KCNMA1P4HTMHDAC1MEN1KMT2A
SCHEMBL16209682 0.81 KMT2A (0.51) KCNMA1P4HTMMEN1AHRKMT2A
SCHEMBL15019683 0.81 P4HTM (0.56) P4HTMHDAC1MEN1AHRKMT2A
SCHEMBL16209987 0.81 ALDH1A1 (0.42) KCNMA1P4HTMMEN1AHRKMT2A
SCHEMBL16209386 0.81 CXCR2 (0.47) KCNMA1P4HTMHDAC1MEN1AHR
SCHEMBL16209517 0.80 P4HTM (0.53) P4HTMMEN1KMT2ANPC1RAB9A
SCHEMBL16209724 0.80 P4HTM (0.54) P4HTMHDAC1MEN1AHRKMT2A
SCHEMBL15019284 0.79 P4HTM (0.47) P4HTMMEN1AHRKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329854-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL IN SIRTUIN BINDING AND MODULATION SMB INNOVATION (US) 2014-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329854-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL IN SIRTUIN BINDING AND MODULATION SIRT1, SIRT3, SIRT2 KCNMA1 3946/4885P4HTM 2015/4885HDAC1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback